Abstract
Oncolytic HSV-1 has been developed as a novel anticancer agent. According to the properties and functions of HSV-1 encoded proteins, several genes have been targeted for engineering of oncolytic HSV-1. As a result, a variety of strategies have been applied to the engineering of oncolytic HSV-1. Success in cancer therapy for solid tumors requires a maximal oncolytic effect; however, recombinant HSV-1 that has been adapted to meet neurotoxicity requirements for the treatment of brain tumors may be too highly attenuated for effective use in solid tumors outside the brain. Recently, there has been renewed interest in the high potency of naturally oncolytic viruses. In this review, we will overview the engineered oncolytic HSV developed thus far, as well as its mechanism of selectivity and its mode of spreading within tumors. We also discuss the preclinical and clinical studies of HF-10, a non-engineered oncolytic HSV-1 virus, and its potential for use in cancer gene therapy.
Keywords: Gene therapy for cancer, solid tumors outside of the brain, engineered oncolytic virus, non-engineered and naturally occurring HSV1 HF10, PKR signaling pathway, activation of immune system, HSV amplicon system, carrier cell strategy
Current Gene Therapy
Title: Non-Engineered, Naturally Oncolytic Herpes Simplex Virus HSV1 HF-10:Applications for Cancer Gene Therapy
Volume: 8 Issue: 3
Author(s): Akihiro Nawa, ChenHong Luo, Lumin Zhang, Yoko Ushjima, Daisuke Ishida, Maki Kamakura, Yasushi Fujimoto, Fumi Goshima, Fumitaka Kikkawa and Yukihiro Nishiyama
Affiliation:
Keywords: Gene therapy for cancer, solid tumors outside of the brain, engineered oncolytic virus, non-engineered and naturally occurring HSV1 HF10, PKR signaling pathway, activation of immune system, HSV amplicon system, carrier cell strategy
Abstract: Oncolytic HSV-1 has been developed as a novel anticancer agent. According to the properties and functions of HSV-1 encoded proteins, several genes have been targeted for engineering of oncolytic HSV-1. As a result, a variety of strategies have been applied to the engineering of oncolytic HSV-1. Success in cancer therapy for solid tumors requires a maximal oncolytic effect; however, recombinant HSV-1 that has been adapted to meet neurotoxicity requirements for the treatment of brain tumors may be too highly attenuated for effective use in solid tumors outside the brain. Recently, there has been renewed interest in the high potency of naturally oncolytic viruses. In this review, we will overview the engineered oncolytic HSV developed thus far, as well as its mechanism of selectivity and its mode of spreading within tumors. We also discuss the preclinical and clinical studies of HF-10, a non-engineered oncolytic HSV-1 virus, and its potential for use in cancer gene therapy.
Export Options
About this article
Cite this article as:
Nawa Akihiro, Luo ChenHong, Zhang Lumin, Ushjima Yoko, Ishida Daisuke, Kamakura Maki, Fujimoto Yasushi, Goshima Fumi, Kikkawa Fumitaka and Nishiyama Yukihiro, Non-Engineered, Naturally Oncolytic Herpes Simplex Virus HSV1 HF-10:Applications for Cancer Gene Therapy, Current Gene Therapy 2008; 8 (3) . https://dx.doi.org/10.2174/156652308784746422
DOI https://dx.doi.org/10.2174/156652308784746422 |
Print ISSN 1566-5232 |
Publisher Name Bentham Science Publisher |
Online ISSN 1875-5631 |
Call for Papers in Thematic Issues
Programmed Cell Death Genes in Oncology: Pioneering Therapeutic and Diagnostic Frontiers (BMS-CGT-2024-HT-45)
Programmed Cell Death (PCD) is recognized as a pivotal biological mechanism with far-reaching effects in the realm of cancer therapy. This complex process encompasses a variety of cell death modalities, including apoptosis, autophagic cell death, pyroptosis, and ferroptosis, each of which contributes to the intricate landscape of cancer development and ...read more
Related Journals
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Extraction, Processing, and Stabilization of Health-Promoting Fish Oils
Recent Patents on Food, Nutrition & Agriculture Modulation of the Endocannabinoid System by Lipid Rafts
Current Medicinal Chemistry Benzothiazole: A Versatile and Multitargeted Pharmacophore in the Field of Medicinal Chemistry
Letters in Organic Chemistry Anticancer Drugs in Liposomal Nanodevices: A Target Delivery for a Targeted Therapy
Current Topics in Medicinal Chemistry Human Serum Albumin Conjugated Biomolecules for Cancer Molecular Imaging
Current Pharmaceutical Design Biocompatible Mater Constructed Microneedle Arrays as a Novel Vaccine Adjuvant- Delivery System for Cutaneous and Mucosal Vaccination
Current Pharmaceutical Design SPECT-CT in Radiotherapy Planning, with Main Reference to Patients with Breast Cancer
Current Radiopharmaceuticals Effects of Polymorphisms of the CYP450 Enzyme Genes on Estrogen Status and the Risk for Osteoporosis
Current Pharmacogenomics Treatment of Colorectal Liver Metastases: A Review
Reviews on Recent Clinical Trials Emerging Therapeutic Targets in Oncologic Photodynamic Therapy
Current Pharmaceutical Design Latest Progress in the Identification of Novel Synthetic Ligands for the Cannabinoid CB2 Receptor
Mini-Reviews in Medicinal Chemistry 3-(4-Geranyloxy-3-Methoxyphenyl)-2-trans Propenoic Acid: A Novel Promising Cancer Chemopreventive Agent
Anti-Cancer Agents in Medicinal Chemistry CCL17/Thymus and Activation-Related Chemokine: A biomarker for Churg-Strauss Syndrome?
Current Biomarkers (Discontinued) siRNA Delivery with Lipid-based Systems: Promises and Pitfalls
Current Topics in Medicinal Chemistry Targeting of Adhesion Molecules as a Therapeutic Strategy in Multiple Myeloma
Current Cancer Drug Targets Growth Factors, Cytokines and Dendritic Cell Development
Current Pharmaceutical Design Pharmacogenomics
Current Drug Metabolism The Inhibitor of Growth (ING) Gene Family: Potential Role in Cancer Therapy
Current Cancer Drug Targets Structural Magnetic Resonance Imaging Findings in Posttraumatic Stress Disorder and Their Response to Treatment: A Systematic Review
Current Psychiatry Reviews MicroRNA-34a Promotes Cardiomyocyte Apoptosis Post Myocardial Infarction Through Down-regulating Aldehyde Dehydrogenase 2
Current Pharmaceutical Design